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Abstract
Background: The absence of trial evidence makes it impossible to determine whether or not
mass screening for lung cancer would be cost effective and, indeed, whether a clinical trial to
investigate the problem would be justified. Attempts have been made to resolve this issue by
modelling, although the complex models developed to date have required more real-world data
than are currently available. Being founded on unsubstantiated assumptions, they have produced
estimates with wide confidence intervals and of uncertain relevance to the United Kingdom.
Method: I develop a simple, deterministic, model of a screening regimen potentially applicable to
the UK. The model includes only a limited number of parameters, for the majority of which, values
have already been established in non-trial settings. The component costs of screening are derived
from government guidance and from published audits, whilst the values for test parameters are
derived from clinical studies. The expected health gains as a result of screening are calculated by
combining published survival data for screened and unscreened cohorts with data from Life Tables.
When a degree of uncertainty over a parameter value exists, I use a conservative estimate, i.e. one
likely to make screening appear less, rather than more, cost effective.
Results: The incremental cost effectiveness ratio of a single screen amongst a high-risk male
population is calculated to be around £14,000 per quality-adjusted life year gained. The average cost
of this screening regimen per person screened is around £200. It is possible that, when obtained
experimentally in any future trial, parameter values will be found to differ from those previously
obtained in non-trial settings. On the basis both of differing assumptions about evaluation
conventions and of reasoned speculations as to how test parameters and costs might behave under
screening, the model generates cost effectiveness ratios as high as around £20,000 and as low as
around £7,000.
Conclusion: It is evident that eventually being able to identify a cost effective regimen of CT
screening for lung cancer in the UK is by no means an unreasonable expectation.
Background
Lung cancer has long been one of the principal causes of
cancer death in industrialised countries. In the 1950s, the
availability of radiography led physicians to believe that
screening for the disease by means of regular chest X-ray
and sputum cytology was both possible and desirable. In
the USA, guidance to this effect was issued and clinical tri-
als were initiated. However, once it had been appreciated
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that the survival gains anticipated in theory were not
being realised in practice, screening began to lose its
appeal [1]. Interest in screening has since been re-awak-
ened, as a result of both developments in imaging tech-
nologies (notably low-dosage, spiral computed
tomography, CT) and novel cancer treatments which
promise improved survival following diagnosis. Clinical
studies of CT screening have been published but, to date,
none has had a comparator group, nor have mortality
improvements as a direct consequence of screening been
demonstrated. No randomised controlled trial (RCT) has
yet reported, although European trials have been initiated
[2,3].
Compared with the enthusiasm expressed in the 1950s
and 1960s, the current advocacy for lung cancer screening
is being tempered with caution [4-6]. In the USA in partic-
ular, practitioners are being urged to await the results of
RCTs prior to implementing CT screening regimens which
could prove both ineffective and costly [7-10]. In the UK
in 2006, a review of CT screening conducted for the
Health Technology Assessment (HTA) Programme con-
cluded that there existed insufficient evidence to demon-
strate either clinical or cost effectiveness in the UK setting.
To fill the evidence gap, the review advocated both the ini-
tiation of UK-centred trials of CT screening and further
research into lung cancer aetiology, quality of life and
related resource use [11].
Collecting evidence by RCT is costly and time-consuming.
In the UK, formal health technology assessment influ-
ences public health care allocation decisions, and it is
unlikely that CT screening for lung cancer would be
implemented in the absence of a demonstration of its cost
effectiveness. By the same token, however, a potential
sponsor of research in the UK would be disinclined to
allocate funds to evaluate screening, unless it was reason-
ably confident that a practical screening programme
would result. Lung cancer researchers thus find them-
selves in a position not unfamiliar to medical researchers
more generally, namely, one of being unable to prove cost
effectiveness without having first conducted a trial, whilst
being unable to secure financial support for a trial without
having first demonstrated cost effectiveness. Modelling
can contribute to breaking the circular logic, by establish-
ing whether or not the existing evidence precludes the
possibility of a programme ever being cost effective.
Existing models
The 2006 HTA review identified six economic evaluation
models of CT screening constructed by Japanese or US
researchers [12-17]. Since the review, an additional Aus-
tralian study has been published [18]. All of the modelled
screening regimens were hypothetical, although two
[12,17] were based on experimental protocols. Six out of
seven of the models produced incremental cost-effective-
ness ratios (ICERs) for screening, expressed in terms of
costs of either expected life years (LYs) or expected qual-
ity-adjusted life years (QALYs) gained. Each model
embodied a sensitivity analysis, to demonstrate the conse-
quences of varying the model's assumptions, and the
ICER results were presented as ranges. Across the studies,
the lowest ratio between minimum and maximum ICERs
presented was 3.3 [16], whilst the highest was 20.0 [14].
In the UK, the National Institute for Health and Clinical
Excellence (NICE) considers evidence of both clinical and
cost effectiveness when deciding on whether or not to
sanction the introduction of new NHS treatments or serv-
ices. According to NICE, interventions with prospective
ICERs below £20,000 per QALY can be accepted as cost
effective, although all those with ICERs up to around
£30,000 merit consideration [19]. The estimated ICERs
from the screening models can be translated into £-ster-
ling at current prices, using both the purchasing power
parity exchange rate at the reference date of each study and
the National Health Service (NHS) HCHS Pay and Price
Index. After so doing, it emerges that, for two of the mod-
els [15,17], the lower end of the ICER range is below
£5,000. Indeed, the £30,0000 NICE threshold appears to
be outside the range of only one of the models [14].
Whilst it might be supposed that this finding strengthens
the case for the cost effectiveness of a UK programme,
there are grounds for distrusting inferences from the ear-
lier models. First, the HTA review describes the quality of
reporting in the studies as "poor", noting that "replication
and verification by the reader is not possible, as the inner
workings of the models are not disclosed" [[11] p.25]. The
lack of transparency precludes the assessment of scientific
quality, so that accepting the models' results as being
authoritative requires a considerable act of faith. Second,
the wide range of ICERs produced by the different models
is symptomatic of the absence of scientific evidence on
major aspects of the disease and its management. With
primary data being unavailable, all of the models have
been driven by assumptions about lung cancer aetiology,
disease progression, management protocols, screening
and treatment effectiveness, survival and the like. Most of
these assumptions are "uncorroborated" [[11] p.41]. Var-
iability in results is compounded in models based on
stage transition and sequencing, because later calculations
rest on the assumptions behind earlier ones.
Third, it is often felt that, because diseases are complex,
models too must be complex, embodying a large number
of parameters and linkages between them. However,
when scientific facts are in short supply, a larger number
of parameters increases the extent of under-identification.
Parameter values have to be assigned by assumption or byCost Effectiveness and Resource Allocation 2008, 6:5 http://www.resource-allocation.com/content/6/1/5
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guesswork, and a model which requires a larger number
of such guesses generates simultaneously a larger number
of permutations of values, all of which will yield solutions
consistent with those few observations which actually do
exist. Thus, over-complex models generate wide ranges of
possible results, with no guidance as to those which are
the more probable.
Finally, and of considerable significance to the question
of cost effectiveness in a UK setting, none of the published
models has been populated with UK data. Whilst the use
of non-UK data might be tolerable with respect to certain
epidemiological parameters, such as aetiology and risk,
clinical practices vary between countries. Moreover, the
costs of labour, equipment, medicines, etc. are likely to be
country- or system-specific [20]. Using only currency
exchange rates, the costs of interventions assessed in other
countries are unlikely to translate accurately as measures
of resource use in the NHS environment.
I conclude that making inferences from earlier models is
insufficient to answer the question of whether or not UK
screening could be cost effective. Accordingly, I adopt a
more direct approach and model a possible UK pro-
gramme. The model, which is based on one originally
developed for colorectal cancer [21], addresses the cost
effectiveness of the screening programme per se, as
opposed to that of a programme consequent upon an
empirically-unsupportable disease progression model. I
employ transparent linear algebra, as opposed to opaque
simulation and, wherever possible, include only parame-
ters whose values can be established scientifically. When
recourse to assumption or guesswork is unavoidable, I
choose values least conducive to making screening appear
cost effective.
Method
An actual protocol for a UK screening programme remains
a matter of conjecture. For example, would screening be
"once-only" or repeated? If the latter, what would be the
inter-round time interval? The defining characteristics of
the target population also remain to be decided although,
for reasons which will become apparent shortly, risk of
disease will certainly be relevant. As the closest approxi-
mation to a future programme, I model a screening proto-
col based on the National Institute for Health and Clinical
Excellence's current guidance for managing patients with
suspected lung cancer [22]. I presume that all individuals
in a cohort targeted for screening receive a CT scan, and
those with negative results thereafter exit the programme.
Individuals recording positive results will be investigated
further, to filter out from eventual treatment those whose
test results are false-positive. Patients with suspected cen-
tral lesions will be investigated by bronchoscopy, whilst
those with peripheral lesions will receive a percutaneous
transthoracic needle biopsy. Other diagnostic options,
such as sputum cytology or positron emission tomogra-
phy (PET) scanning, will be reserved for cases where either
bronchoscopy or needle biopsy is deemed impracticable.
Subjects in whom cancer is confirmed will proceed to
treatment.
The costs of the screening programme additional to the
costs resulting from symptomatic presentation are there-
fore (i) the costs of CT-testing all individuals in the screen-
ing cohort, plus (ii) the costs of investigating all CT-
positives, plus (iii) the costs of treating the true-positives,
minus (iv) the costs of confirming and treating cancer
amongst those who, in the absence of screening, would
have presented symptomatically. The benefits of screen-
ing – a longer life expectancy as a result of cancers being
detected and treated earlier than would have occurred
otherwise – are confined to those individuals who record
true-positive results.
In the remainder of the Methods section, all of the
model's parameters and functional forms are defined, and
the baseline values are assigned. For convenience, the def-
initions of the variables, their base values and the sources
are summarised in Table 1.
Model structure
￿ All costs and outcomes subsequently defined are addi-
tional to those which would accrue to the management of
an unscreened cohort of equal size.
￿ The screening programme requires each of N subjects to
take a screening test, at a cost of S per subject. Test sensi-
tivity, specificity and disease prevalence are X, Y and P,
respectively. Those recording negative test results exit the
programme, whilst those recording positive results will be
investigated further, at unit cost I.
￿ For the cohort, the expected number of true positive test
results = NPX, whilst the expected number of false posi-
tives = N(1-P)(1-Y). We assume that the investigation is
definitive, i.e. always yields the correct diagnosis.
￿ The expected cost of screening N subjects and of detect-
ing the cancers equals the costs of the tests undertaken,
plus the costs of investigating the positives, both true and
false:
NS + NPXI + N(1-P)(1-Y)I (1)
￿ Detected cancers will be treated, and screening influ-
ences treatment in three ways. First, in comparison with
symptomatic presentation, screen-detection moves the
time of treatment forward, i.e. treatment costs are incurred
earlier. Second, as the cohort ages, some of the individualsCost Effectiveness and Resource Allocation 2008, 6:5 http://www.resource-allocation.com/content/6/1/5
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who record true positives at the time of screening, and
who are treated accordingly, would have died of other
causes before presenting with symptoms, had screening
not been available. These subjects would then have
required no cancer-specific treatment. Third, to be suc-
cessful, screening will change the stage distribution of
identified disease in favour of earlier stages, and the costs
of early-stage treatment may differ from those of late-
stage. The net additional cost of treating each cancer
detected by screening, T, will therefore be governed by (i)
the lead time which, coupled with the interest rate, deter-
mines the degree of discounting on costs which are
incurred in the future, (ii) the probability of subjects with
undetected cancers dying before presentation, (iii) the
costs of treating both screen-detected and symptomati-
cally-presenting cancers. The gross costs of diagnosing and
treating a screen-detected cancer are represented as GCT,
and those of a symptomatically-presenting cancer as GSP.
The time elapsing between screen detection and sympto-
matic presentation is E, the discount rate is R, and the
probability of an individual of screening age surviving
until presentation is C. Then:
￿ Confirmed false positives on investigation exit the pro-
gramme, incurring no further costs. The total costs of the
screening programme additional to no screening, i.e. test
costs, investigation costs, and the extra treatment costs of
the true positives, are therefore:
NS + NPX(I + T) + N(1-P)(1-Y)I (3)
￿ As a result of screen-detection and early-stage treatment,
each true positive gains a benefit, B, measured in life years
(LYs) or quality-adjusted life years (QALYs). The total
expected health gain for the screening programme is
therefore:
NPXB (4)
￿ The ICER for the screening regimen is equation (3)
divided by equation (4). Further division of both numer-
ator and denominator by N produces:
￿ The numerator of equation (5) is the expected cost of the
screening regimen per person screened, whilst the denom-
inator is the expected benefits of screening per person
screened.
Unit costs
In England, the ostensible costs of many clinical proce-
dures are presented as tariffs. Tariffs are based on cost esti-
mates routinely collected from individual health care
providers, each of which is expected to employ a standard
template for recording resource use. The variation in unit
costs across providers is typically wide and, as collection is
far from transparent, it is not evident that tariff-based
costs necessarily reflect true economic costs. However, tar-
iffs are intended to form the foundation of National
Health Service (NHS) accounting, so the use of tariff-costs
in a model of a potential NHS screening programme
would seem appropriate. The tariff for a CT scan is £56
[23], although any future mass screening programme will
require an administrative structure. Some ten years ago, it
TG
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Table 1: Glossary of model parameters
Definition Baseline value & source
A Age – sub-scripted CT (age at CT screening) and SP (age at symptomatic presentation)
B Health benefit gained as a result of early detection, per cancer 1.7 QALYs – determined by the survival model
C Probability of an individual of screening age surviving until symptomatic presentation 0.88 – UK Life Tables [38]
E Lead time (years between detection at screening and symptomatic presentation) 8 years – [44, 45]
GCT Gross costs of screen-detecting and treating a case of lung cancer £12,000 – [26, 27]
GSP Gross costs of diagnosing and treating a cancer presenting symptomatically £7,050 – [26, 27, 29, 30]
I Cost of investigating a positive resulting from the initial screening test £503 – Cost of bronchoscopy [23]
MA Mortality rate at age A
N Numbers of individuals in a cohort – sub-scripted CT (screening) and SP (symptomatic presentation)
P Prevalence of lung cancer in the population targeted for screening 1% – average of [34-36]
R Discount rate 3 1/2% – [46]
S Unit cost of the initial screening test (CT scan). £60 – [23]; includes £4 allowance for administration
T The net additional cost of treating a screen-detected cancer, as opposed to one 
presenting symptomatically
£7,286 – calculated from C, E, GCT, GSP and R
X Sensitivity of the screening test 85% – [11, 14, 31]
Y Specificity of the screening test 85% – [11, 31, 32]Cost Effectiveness and Resource Allocation 2008, 6:5 http://www.resource-allocation.com/content/6/1/5
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was estimated that the English cervical screening service
expended £6 million on administering the screening of
over 3 million women each year [24]. To allow for the cost
of administration, therefore, I add £4 to the cost of each
scan and set the unit cost of the CT screening test at £60.
This cost (and all subsequent costs) is expressed in 2004
prices.
Of the investigation alternatives under consideration,
only PET is more costly than bronchoscopy, although PET
scanning would be reserved for the minority of cases
where other diagnostic methods would fail. A UK study
[25] has suggested that bronchoscopy is likely to be
appropriate in the majority of cases. For my model, there-
fore, I assume that all screening subjects with positive CT
results will be investigated by bronchoscopy, an assump-
tion which appears likely to overstate the expected unit
costs of investigation. According to the NHS tariff, the unit
cost of bronchoscopy is £503 [23].
The costs of treating lung cancer are not clear-cut, as the
national tariff describes unit costs for procedures rather
than for patients. Any patient entering treatment might
require more than one procedure and it is likely that few
patients will undergo precisely the same treatment path
following diagnosis. In theory, therefore, the range of
potential treatment costs is extremely wide. For model
purposes, I employ treatment cost estimates derived from
two empirical studies, each of which employed an audit,
as opposed to a tariff, approach. These studies calculated
patient-specific costs for 253 patients in the Trent region
[26] and for 109 patients in Newcastle [27], each man-
aged over a maximum of 4 years. Expressed at 2004 prices,
the studies produced mean treatments costs of approxi-
mately £8,800 and £14,200 per case, respectively. The
higher costs in the second study appear to be attributable
to longer mean lengths of hospital stay during each of the
various treatment phases. I accordingly choose an inter-
mediate value of £12,000 per case to represent the gross
cost of treating a screen-detected cancer.
Lung cancers in the UK are typically diagnosed at later
stages than in many other countries [28] and around 55
per cent do not receive any active anti-cancer therapy [29].
For modelling, I presume that 45 per cent of patients pre-
senting symptomatically receive the same treatment as
those whose cancers have been screen-detected, whilst the
remainder receive only palliative care. Palliative care for
lung cancer has been costed at £3,000 per patient [30].
Thus, the expected costs of treating cancers which present
symptomatically are [(0.45)(£12,000) + (1-
0.45)(£3,000)] = £7,050.
Test parameters
The yield of a screening programme is influenced by the
sensitivity and specificity of the CT screening test, and by
the prevalence of cancer in the target population. The pub-
lished estimates of the sensitivity of a single CT screen vary
considerably, from around 55 per cent to over 90 per cent.
The lower values tend to be reported by studies at their
earliest phases and they therefore probably represent
results taken from "high on the learning curve". The real-
istic minimum using experienced testers appears to be
around 80 per cent [11]. Although meta-analyses [14,31]
of independent studies have produced averages of esti-
mated test sensitivity in excess of 90 per cent, I shall use a
more conservative value of 85 per cent. The same meta-
analyses produced average specificities of around 83 per
cent, although studies reporting more recently have cited
specificities of between 93 and 97 per cent [11]. The false-
positive rate reported in a Mayo Clinic sample after five
years [32] also implies a specificity within this range. It is
probable that improving specificity over time can be
explained by the accumulation of experience also. Again,
I shall use a relatively conservative value, namely, a specif-
icity of 85 per cent.
Lung cancer is a disease of the elderly. Only at the peak
ages of presentation, from the mid-70 s onwards, does the
incidence rate in England exceed 0.5 per cent. The screen-
ing debate, however, is rarely couched in terms of the gen-
eral population. The subjects of all of the clinical studies
of CT screening have being high-risk, selected using crite-
ria such as age, occupation and history of cigarette smok-
ing. The lung cancer prevalence rates reported in such
studies range between 0.4 per cent and 13.6 per cent [33],
with the USA studies typically reporting the higher preva-
lences [11]. As a basis for modelling a UK programme, I
assume that the population targeted for screening will
also be selected on the basis of risk, and will exhibit a
prevalence of disease higher than that of the general pop-
ulation. I use a prevalence value of 1 per cent, the
weighted average of the prevalences reported in three
European CT screening studies, namely, those based in
Germany [34], Ireland [35] and Italy [36].
Health gains
I estimate LY gains from screening using a survival
approach. Life Tables provide mortality rates and survival
rates, by age and by sex. The mortality rate increases with
age, and the Life Table data enable the plotting of a sur-
vival curve, which maps the number surviving from a
cohort of individuals at any given age, A. In Figure 1, the
curve labelled "Normal" pertains to a cohort whose mem-
bers are subject to all of the normal causes of death; this is
the curve produced using the Life Table data directly. To
estimate an individual's life expectancy at any chosen age,
A, we calculate the number of "years alive" in the cohortCost Effectiveness and Resource Allocation 2008, 6:5 http://www.resource-allocation.com/content/6/1/5
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at each particular age. Summing the "years alive" from A
to the oldest possible age in the Life Table gives the total
number of years lived by cohort members from age A. In
effect, this is the area under the survival curve. The expec-
tation of life at age A is then obtained by dividing the total
number of years lived by the number in the cohort alive at
age A [37].
Now consider a cohort whose members are destined to
contract lung cancer. Prior to presentation, the cohort will
decline in numbers as for the "Normal" cohort. Following
presentation, the current evidence from the UK suggests
that most will die within the one or two years immedi-
ately following diagnosis and treatment. Mortality rates
for those who do survive will eventually revert to those
appropriate to a normal cohort. This cohort is modelled
as "Symptomatic" in Figure 1, with presentation occurring
at age ASP. Again, the area under the curve represents the
total number of years lived by that cohort.
Finally, consider a cohort destined to contract cancer, but
where the cancer will be detected by pre-emptive CT
screening at age ACT. Any intervention entails an increased
mortality risk with the result that, initially, the relative
decline in numbers in this cohort will be greater than the
relative decline of those in either a normal or a pre-symp-
tomatic cancer cohort. However, presuming that earlier
detection will indeed offer improved longer-term survival,
the relative decline will be lower than for the symptomatic
cohort subsequently (as represented by "Screened" in Fig-
ure 1). From the geometry of Figure 1, it is apparent that
the LY gains from screening would fall were (i) survival
rates following symptomatic presentation to improve, (ii)
survival rates following screen-detection to decline, (iii)
lead time, (ASP-ACT), to increase.
With respect to the calculations, the "Normal" curve uses
UK Life Table data for males, estimated for the years
2003–5 [38]. I model survival in a male, as opposed to
female, cohort, for two reasons. First, for any given age at
intervention, males face a shorter life expectancy and, sec-
ond, lung cancer is more prevalent amongst males. For a
cancer cohort, mortality rates beyond ASP are modified
using rates derived from Cancer Registry survival data. At
present, 1-year survival following diagnosis and treatment
in the UK is around 22 per cent, falling to around 6 per
cent at 5 years [39]. For those presenting in their 60 s, the
rates are more favourable, at around 27 and 8 per cent,
respectively [40]. Data from the USA indicate that survival
continues to fall beyond 5 years, although at an apprecia-
bly gentler rate [41]. This pattern of initially-high mortal-
ity, quickly tapering off, suggests a negative exponential
formulation for mortality rate. For "Symptomatic", I
define the mortality rate at ages A after presentation (MA)
as:
MA = 0.7*(A - ASP)-1.3 (A - ASP) = 1, 2, 3,....
The estimated rates are applied up to the age at which the
normal mortality rate exceeds the estimated rate and,
thereafter, the rate following symptomatic presentation
defaults to the normal rate. This function actually over-
states survival somewhat, as it implies 1-, 5-, and 10-year
survival rates of 30, 14 and 11 per cent, respectively.
As regards long-term survival following CT screen detec-
tion within a clinical trial, the most authoritative data
reported thus far are from the ELCAP investigators [42].
They report a 1-year survival rate of around 95 per cent,
with a 10-year survival of 80 per cent. This result is corrob-
orated by a reported 10-year survival of 83 per cent for a
mobile screening programme in Japan [43]. These data
form the basis of our "Screened" survival curve, and we
model the mortality rate following screen-detection as:
MA = 0.1*(A - ACT)-0.8 (A - ACT) = 1, 2, 3,....
As before, the estimated rates are applied up to the age at
which the normal mortality rate exceeds the estimated
rate and, thereafter, the rate following screen detection
defaults to the normal rate. This function under-states
post-screening survival as reported, because it implies 1-,
5- and 10-year survival rates of 90, 77 and 70 per cent,
respectively.
The optimal age at which to screen remains to be estab-
lished. As the survival model was informed principally by
the ELCAP data, I set the age at screening in the model to
the reported average age of those screened in that study,
namely, 61 years. There exists no evidence as to when such
cancers would have presented symptomatically although,
Cancer survivors over time Figure 1
Cancer survivors over time.
Age 
Number 
ACT ASP
Symptomatic   
Normal    
Screened    
NCT
NSPCost Effectiveness and Resource Allocation 2008, 6:5 http://www.resource-allocation.com/content/6/1/5
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given they are occurring in a high-risk population, presen-
tation would presumably occur earlier than in the general
population. Those involved in the European CT screening
trial and in the ELCAP study [44,45] have conjectured that
lead time could be 4–8 years. I used the value least favour-
able to the screening scenario, namely, 8 years.
NICE guidance [46] requires that health outcomes be dis-
counted at the same interest rate as that used for discount-
ing costs, namely, at 3 1/2 per cent per annum. In
addition, NICE requires health gains to be expressed as
quality-adjusted life years (QALYs), to facilitate compari-
sons with other health care interventions. Longitudinal
research on quality of life following treatments for lung
cancer is meagre. Quality of life seems to be poor in the
immediate post-treatment phase but improves thereafter,
especially amongst the longer-term survivors [47]. Evi-
dence of health state utilities following treatment comes
only from cases of symptomatic presentation although it
might be expected that, were cancer to be detected and
treated at the earliest stages, the health state utilities of
patients would be noticeably higher. I used a rounded
value for the quality adjustment coefficient identified for
symptomatic presenters, namely, 0.6 [48-50], implying
that 1 LY gained = 0.6 QALYs gained.
Results
The survival model predicts that males in the general UK
population can expect, when aged 61 years, to live a fur-
ther 19.8 years, i.e. until 80–81 years of age. It predicts
that those individuals destined to present with cancer
symptomatically will live a further 10.9 years, i.e. until
around the age of 71–72 years. With an assumed lead time
of 8 years, this estimated age at death implies a mean sur-
vival after symptomatic presentation of nearly 3 years.
Extrapolating the UK's 5-year UK survival data to 10 years,
mean survival after presentation is actually 1.9 years. As
intended, the model over-states post-presentation sur-
vival.
The model predicts that individuals whose cancers have
been detected by screening at the age of 61 will survive a
further 16.7 years, dying at the age of 77–78 years. Having
a cancer which is detected and treated at the earliest stages,
therefore, costs the individual 3.1 years of normal life.
Compared with symptomatic presentation, however, the
health gains per cancer detected at screening are 5.7 LYs
(subtraction not exact owing to rounding). The absence of
trial evidence makes independent validation of this result
impossible. Perhaps the best that can be said is that, if we
are willing to presume that screen-detected cancers will
typically be at stage 1, whilst symptomatic ones will
present at stage 3 or 4, then this gain is consistent with the
difference in median survival times of 4–6 years reported
in the Mayo Clinic series [51]. Given the assumed transla-
tion between life years and QALYs, the expected health
gain per cancer screen-detected equals 3.4 QALYs. These
QALYs are obtained over a period of up to forty years fol-
lowing screening, and the discounted gain is 1.7 QALYs.
The survival model generates two results necessary to
complete the treatment cost calculation, equation (2).
First, it specifies the lead time, E = 8. Second, between the
ages of 61 and 69, the Life Table data predict a decrease in
the number of survivors, (NCT-NSP), of 12 per cent, i.e. C
= 0.88. Given that we have already specified R = 3 1/2 per
cent, GCT = £12,000 and GSP = £7,050, it follows that T =
£7,286.
Values for all the parameters in equation (5) have now
been specified. Substitution into the equation produces
an expected incremental cost per person screened of £201.
This comprises the test cost of £60, £75 expended on
investigating the false positives, and £66 expended on
investigating and treating the true positives, net of
expected treatment costs following symptomatic presenta-
tion. The expected incremental benefit per person
screened equals 5.3 quality-adjusted life days, and the
incremental cost effectiveness ratio amounts to £13,910.
Sensitivity analysis
The consequences of changing values for the sensitivity
and specificity parameters can be traced through equation
(5). As noted earlier, some of the clinical studies have
reported values in excess of 90 per cent for both. Allowing
the sensitivity parameter to increase by 5 percentage
points (from 85 to 90 per cent) increases the number of
true positive test results. A higher yield from screening is
accompanied by higher costs, although the net effect is to
lower the ICER to £13,392. This represents a fall of around
4 per cent from the baseline estimate. An equivalent rise
in specificity reduces the number of false positives being
sent for unnecessary investigation. Expected cost is
reduced, there are no consequences for expected health
benefit, and the ICER falls by around 12 per cent, to
£12,186. The two changes combined produce a 15 per
cent fall in the baseline ICER, to £11,764.
Other things remaining equal, the cost effectiveness of
screening increases as the prevalence of cancer in the tar-
get population increases. A screening programme for a tar-
get population with a prevalence of 1.5 per cent, rather
than the assumed 1 per cent, would have an ICER of
£10,784, around 22 per cent lower than the baseline esti-
mate. A prevalence of 2 per cent would produce an ICER
of £9,221, 34 per cent lower than baseline. Contrariwise,
the prevalence of lung cancer in the UK's general male
population aged 60–69 years is considerably lower, at
around 0.2 per cent. Screening with this level of preva-
lence in the target population yields an ICER of £51,424,Cost Effectiveness and Resource Allocation 2008, 6:5 http://www.resource-allocation.com/content/6/1/5
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nearly four times the baseline estimate and well above the
NICE threshold for cost effectiveness.
NICE is conscious that unit costs can vary locally and the
guideline [23] presents the ranges of values collected
across different providers. The range for the CT scan is
£50–103, suggesting that the cost of CT scanning could,
under some conditions, be almost double that of the base-
line estimate. Were we to assume that unit CT costs were
indeed to be twice as high as our baseline value, i.e. £120
as opposed to £60, the estimated ICER would rise from
£13,910 to £18,065, an increase of approximately 30 per
cent. The guideline's upper bound for the cost of the bron-
choscopy investigation is £721. Using this value in place
of £503 increases the ICER by 17 per cent above baseline,
to £16,280. Making both cost adjustments simultane-
ously increases the ICER by 47 per cent, to £20,434.
This having been said, it is perhaps more reasonable to
expect that the unit cost of procedures in a specific screen-
ing context will be lower than when measured in general
usage, owing to economies of specialisation. For example,
a detailed analysis of the costs of flexible sigmoidoscopy
employed in colorectal cancer screening clinics [52] pro-
duced a unit cost of less than one-half of the contempo-
rary tariff price for sigmoidoscopy estimated in general
settings [53]. Were the costs of investigation in lung can-
cer screening to follow the same pattern, the ICER for
screening would fall. Halving the cost of investigation,
from £503 to £252, reduces the estimated ICER from
£13,910 to £11,182, a fall of around 20 per cent from
baseline.
It is known that survival rates following lung cancer treat-
ment in the UK are low in comparison with those
achieved elsewhere in Europe. The reasons for this remain
uncertain, although diagnostic delay and (non-)use of
novel therapies have been advanced as explanatory fac-
tors. Countries such as France and the Netherlands
achieve 1-year survival rates of around 40 per cent and 5-
year rates in excess of 10 per cent [54]. Were the survival
rates of symptomatically-presenting cancers in the UK to
move towards these levels, it follows that the life year
gains realisable from CT screening would fall correspond-
ingly. The "French approach" can be simulated by using a
different mortality rate function in the model for those
who present symptomatically, namely:
MA = 0.6*(A - ASP)-1.0 (A - ASP) = 1, 2, 3,....
This function implies 40 per cent survival at one year, and
17 per cent at 5 years. The model now predicts a smaller
health gain from screening, namely, 5.4 LYs rather than
the baseline 5.7 LYs. Obtaining superior survival follow-
ing symptomatic presentation, however, must have
resource implications. In France, 75 per cent of patients
are in receipt of active, as opposed to palliative, treatment
[55], compared with less than 50 per cent in the UK. To
accommodate a higher proportion of patients in active
treatment in the model, GSP  can be re-specified as
[(0.75)(£12,000) + (1-0.75)(£3,000)] = £9,750, which is
higher that the baseline value of £7,050. The net effect of
more treatment and better survival is an ICER for screen-
ing of £13,786, around 1 per cent lower than the baseline
estimate. From the point of view of the cost effectiveness,
therefore, the impact of the improved survival of sympto-
matic presenters which results from more treatment is
counter-balanced by the increased costs of that treatment.
The estimate of health gain has been based on data for
males, although it is a simple matter to replicate the
screening regimen for women. Using the Life Tables for
females we find that, age-for-age, modelled life expectan-
cies for women exceed those of men for each of the three
survival curves. Normal life expectancy for UK women at
61 years of age is 22.8 years, compared with men's 19.8,
for example, and the model estimates female life expect-
ancy for screen-detected cancer at 18.5 years, compared
with 16.7 for males. For a women with lung cancer, the
expected gain from screening is 7.0 LYs, compared with a
man's 5.7 LYs. The female health gain translates into 2.0
discounted QALYs, and there is no reason to suppose that
the costs of screening would differ between men and
women. Other things remaining equal, the baseline ICER
for female CT screening is £11,710, 16 per cent lower than
the equivalent ICER for males.
The modelled screening regimen entails a single, preva-
lence, screen for each subject. It is nevertheless evident
from the literature that some screening enthusiasts have
contemplated regimens involving further rounds of
screening. Whilst not set up to consider such regimens
specifically, some consequences can be inferred from the
model. For example, two CT scans separated in time by
less than 12 months would serve to increase the sensitivity
of the screening regimen although, almost inevitably,
with some loss of specificity. Such a regimen would entail
test costs of £120, as opposed to £60. If sensitivity was
thereby increased to 90 per cent, whilst specificity fell to
80 per cent, the ICER for such a regimen would, according
to our model, be £18,944, a 36 per cent increase over
baseline. Reverting to the original scenario of a single
screen at age 61, suppose a second round of screening
were to occur 3 years later, at age 64, now with a lead time
of 5 years. The model suggests that the prevalence of can-
cers available for detection in the second screen would
have to be around 6.5 per 1,000 for the second round to
be as cost effective as the first. It is not evident whether the
disease progresses sufficiently rapidly to produce this rate,
although it is clear that the cost effectiveness of a secondCost Effectiveness and Resource Allocation 2008, 6:5 http://www.resource-allocation.com/content/6/1/5
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round of screening will vary directly with effectiveness of
the first.
Finally, two of the survival model's assumptions merit
consideration. First, the cancer-related survival curves are
departures from the general population survival curve,
derived from the Life Tables. As the individuals being
modelled are destined to succumb to lung cancer, it
would seem inevitable that they are less healthy than the
general population and must experience significant co-
morbidity. To reflect this, the "Normal" survival curve
should have been based on higher age-specific mortality
rates, although independent Life Tables for this morbid
population do not, of course, exist. A simulation which
increases all mortality rates by age by an arbitrary 10 per
cent for the model's "Normal" curve suggests a fall in
expected QALY gain from 1.7 to 1.6. The ICER rises by 6
per cent, to £14,727. The net effect is actually quite small,
because health gain is determined by the difference
between the "Symptomatic" and the "Screened" curve and
each depends on the same "Normal" curve.
Second, the assumed lead time in the model was set to the
maximum currently deemed possible, although evidence
could, of course, eventually reveal it to be shorter. If the
lead time is halved – four years rather than the assumed
eight – expected costs fall by around 5 per cent, owing to
the costs of managing symptomatic presenters moving
forward in time. A shorter lead time implies earlier deaths
for the symptomatic cases, and the expected QALY gains
from screening rise from 1.7 to 3.1. The ICER becomes
£7,226, 48 per cent lower than the baseline estimate.
Discussion
It is evident from the model that the appropriate selection
of screening targets is crucial for efficiency. Indeed, it is
unlikely that un-targeted screening could ever be justifia-
ble economically. Progressively restricting the programme
to higher-risk individuals improves the economic case for
screening in two ways. First, it reduces the numbers eligi-
ble for screening, and thereby lowers overall programme
costs. Second, the selection of higher-risk individuals
implies higher prevalence in the target population, and
higher prevalence reduces the ICER, other things remain-
ing equal. The economic viability of a UK screening pro-
gramme is therefore predicated on the screeners' ability to
establish appropriate criteria for identifying targets. Some
success in this respect has already been reported [56,57].
It is probable that criteria will include not only disease-
related risk factors such as cigarette smoking and occupa-
tional exposure to carcinogens but also factors related to
capacity to benefit from treatment after detection [58].
Earlier it was noted that, were age at screening to be the
only consideration, it would be more cost effective to
screen women than to screen men, although this calcula-
tion failed to allow for the lower disease prevalence typi-
cal amongst females. These conclusions will require
reconsideration, if an anticipated growth in prevalence
amongst females relative to males eventually materialises
[59]. At present, when both age and prevalence are taken
into account, it is more cost effective to screen men than
it is to screen women. Within the model, screening
women is as least as cost effective as screening men when
female prevalence is at or beyond around 80 per cent of
male prevalence.
The calculations in the model conform to NICE's current
accounting conventions, as would seem appropriate for
the UK (or, more accurately, for England). However, paro-
chial accounting conventions limit the capacity to gener-
alise from the results [60], and NICE conventions do
differ somewhat from those of most other countries. In
particular, cost effectiveness evaluation requires a defini-
tion of perspective, i.e. identifying those to whom the
costs and benefits accrue. NICE requires that the govern-
ment or NHS perspective be used in its evaluations, as it
sees itself as being concerned with the best uses of the
public health care budget [61]. Most other countries using
evaluation results to inform policy consider the societal
perspective to be the more appropriate i.e. the relevant
costs and benefits are those which accrue to any member
of the entire population [62].
The use of different accounting conventions can yield dif-
ferent conclusions. For example, social costs are likely to
be higher than NHS costs, for four reasons. First, social
costs encompass all NHS costs, by definition. Second,
attending for screening inevitably entails the incurring of
time and travel costs on the part of those being invited.
These costs can be sizeable: in a trial of clinic-based
screening for colorectal cancer, time and travel costs
added 26 per cent to gross NHS costs of all detection and
treatment [63]. Third, screening according to our model
requires people to undergo treatment during their early-
60 s (when they might be employed), rather than in their
late-60 s (when they might have retired). It is possible,
therefore, that society will incur net production losses
from earlier detection, as a result of workers undergoing
treatment. Fourth, the informal sector (family or charity)
provides a considerable input to terminal care, above and
beyond that provided by the NHS. As the estimated bene-
fits of screening are the same under either evaluation per-
spective, it follows that screening will be less cost effective
when judged from a societal perspective than when
judged from an NHS perspective. The magnitude of all
these additional costs are, at present, unknown, so no seri-
ous assessment can be made of the likely difference
between the NHS-perspective and the societal-perspective
ICERs.Cost Effectiveness and Resource Allocation 2008, 6:5 http://www.resource-allocation.com/content/6/1/5
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NICE's current position requires it to follow UK Treasury
guidance in discounting costs and benefits at the same
rate of 3 1/2 per cent. Academic debate over the discount-
ing of benefits nevertheless persists, especially in circum-
stances of prevention where life years might accrue only in
the distant future [64,65]. Some economists have argued
that QALYs are logically un-discountable or, if they are
discounted, the rate should be lower than that used for
costs. Indeed, the latter was NICE's own position until
2004. The effect of discounting benefits at a lower rate in
our model is considerable. At a zero discount rate, unit
health gains change from to 1.7 QALYs to 3.4, and the
ICER falls to £6,873. Discounting benefits at a zero rate
would enable the original ICER to be maintained even if
social costs were twice NHS costs. In fact, doubling all
costs and failing to discount benefits in the model pro-
duces an ICER of £13,746, almost identical to the baseline
estimate. It should be noted that NICE's current conven-
tions have attracted scientific criticism [66] and it is by no
means clear that these conventions are sustainable over
the longer term.
Although models can provide guidance in the face of lim-
ited evidence, they cannot overcome the evidence vacuum
which characterises several important real-world aspects
of screening. First, practically nothing is known currently
about how individuals would respond to an invitation to
participate in mass lung cancer screening, beyond the like-
lihood of expressing an interest in principle [67]. Willing-
ness to be screened for cancer is predictable from
individuals' characteristics and, ironically, individuals
who smoke tobacco appear to be amongst those least
inclined to engage in health promotion activities. Smok-
ing, for example, is associated with non-participation in
US cervical [68] and colorectal [69] screening. A survey of
potential users of CT screening in the USA revealed that,
compared with non-smokers, a significantly lower pro-
portion of smokers would consider being screened or
would opt for treatment if a cancer were to be screen-
detected [70].
With respect to the cost effectiveness model, a low compli-
ance rate is of little consequence. With all the costs in the
model being variable, reducing participation in screening
by, say, one half, halves the benefits obtained but it also
halves the costs, and the ICER as calculated remains
unchanged. The cost effectiveness of a real-world pro-
gramme would be affected significantly by a low partici-
pation rate only if fixed costs (e.g. those of administration
and management) were sizeable. The refusal of treatment
following detection is more damaging to the case for
screening. If a screened subject refuses treatment, s/he
incurs screening costs to no benefit, thereby effecting an
increase in the programme's ICER. Were 1-in-5 screen-
detected cancers in the model to refuse treatment, the
ICER would rise by 25 per cent. In a Japanese study [43],
however, only 5 per cent of patients with screen-detected
cancers were reported as having refused treatment.
Second, the absence of experimental data means we have
no clear understanding of the future impact of lung cancer
screening on risk behaviour, specifically, cigarette smok-
ing. On the one hand, it has been argued that those
attending for screening are particularly susceptible to
smoking cessation interventions [71]. On the other,
smokers might feel that opportunities for early detection
of cancer reduce the incentive to curtail their risky activi-
ties. Third, positive screening results are likely to create
psychological morbidity, irrespective of any subsequent
survival gains, as has been demonstrated for cervical
screening [72]. These remain unaccounted for in our lung
cancer model, simply because the effect is unknown.
Finally, it is probable that a CT screening programme
would generate quantities of "incidentalomas" [73], that
is, asymptomatic abnormalities other than lung cancer
detected by serendipity. Again, the consequences for cost
effectiveness are unpredictable. Whilst the detection of
incidentalomas is often viewed negatively, in view of the
risks of over-treatment or of creating anxiety, a positive
consequence is also possible. A screening programme
which leads to the cost effective treatment of detected
abnormalities in addition to lung cancer is might well be
producing greater health gain for less-than-proportionate
cost, thereby making the screening programme even more
cost effective than it nominally appears.
Conclusion
Using a model whose parameters were specified by
recourse to the available evidence, I modelled a plausible
screening scenario with an ICER below the NICE thresh-
old. Therefore, the answer to the question – could CT
screening for lung cancer ever be cost-effective in the UK?
– must be squarely in the affirmative. I stress that this
model is offered as a prelude to obtaining experimental
evidence, and not as a substitute for such evidence. This
having been said, it follows that, were a future clinical/
economic trial to reproduce the parameter values
employed in this model, then a screening programme
consistent with both model and trial would itself be cost
effective.
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